The most common TRAEs leading to dose interruption were neutropenia (eight patients (28%)), anemia and increased AST (each three patients (10%)) and thrombocytopenia and increased ALT (each two patients (7%)). This evidence concerns the gene GPT and Thrombocytopenia.